Sepsis AI Tools: FDA and Workflow Checks

Evaluate sepsis AI tools by FDA status, intended use, data inputs, clinician suspicion, alert routing, local validation, privacy, and governance.

Relevant product screenshot for Sepsis AI Tools: FDA and Workflow Checks: Bayesian Health
Representative source image: official Bayesian Health product page.
Quick answer: Sepsis AI tools should be evaluated as high-risk clinical decision support or medical-device software. Confirm whether the product is cleared for continuous monitoring or for suspected-sepsis risk assessment, validate performance locally, define who acts on alerts, and monitor missed cases, false positives, time to treatment, equity, and alert fatigue after launch.

Who this guide is for

Sepsis committees, emergency departments, hospitalists, infectious disease leaders, nursing, quality, clinical informatics, CMIOs, and AI governance teams evaluating sepsis detection or risk workflows.

What makes this workflow different

Sepsis AI spans continuous monitoring, suspected-sepsis diagnostics, EHR alerts, biomarkers, and care bundles, so intended use changes the safety, FDA, and workflow checks.

What to verify before using it

Risk level and safe use

Medical riskHigh
Best first stepWrite the workflow in one sentence, decide who reviews the AI output, and test with a small controlled pilot before expanding.
Recommended postureUse AI as supervised workflow support. Verify sources, privacy, human review, and regulatory fit before relying on outputs.

Source-backed products for this workflow

These profiles are not rankings. They are starting points for checking vendor claims, privacy terms, FDA or regulatory posture, evidence, and workflow fit.

Clinical operations and revenue cycle

Bayesian Health

Bayesian Health describes a real-time clinical intelligence platform that reads EHR signals, adapts to patient baselines, surfaces risk, guides clinicians inside workflows, and reports published and real-world outcome claims; FDA records list K250680 for the Bayesian Health Sepsis Flagging Device as a Class II software device to aid sepsis prediction or diagnosis.

Best for
Hospitals evaluating governed clinical AI for sepsis, deterioration, or other inpatient risk workflows where alerts need context, clinician trust, and performance monitoring.
First check
Whether the deployment uses the FDA-cleared Bayesian Health Sepsis Flagging Device K250680, another Bayesian module, or a broader clinical pathway workflow.
Sources
7 official sources
Precision medicine and data

Prenosis Sepsis ImmunoScore

Prenosis describes Sepsis ImmunoScore as an FDA De Novo-authorized AI sepsis diagnostic and predictive tool that combines up to 22 patient parameters, biomarkers, vital signs, demographics, and EHR data; FDA records list DEN230036, and Roche navify materials describe cloud-based algorithm-suite deployment and intended-use boundaries.

Best for
Hospitals evaluating transparent sepsis risk stratification that combines clinical data and biomarkers with EMR-integrated review for suspected sepsis workflows.
First check
FDA De Novo DEN230036 intended use, patient eligibility, blood-culture-order requirement, 24-hour risk window, and prescription-use limits.
Sources
4 official sources
Clinical operations and revenue cycle

Mednition KATE

Mednition describes KATE as a clinical AI platform for emergency department triage, sepsis recognition, and clinical analytics that reads structured and unstructured EHR data; company materials describe KATE Sepsis as having FDA Breakthrough Device Designation, while FDA guidance explains that designation is not the same as marketing authorization.

Best for
Hospitals evaluating AI as a triage safety net for emergency nurses where alerts can be governed through ED, sepsis, nursing, quality, and informatics workflows.
First check
Which module is in scope: KATE Triage, KATE Sepsis, Clinical Data Engine, reporting dashboards, or retrospective cohort analytics.
Sources
6 official sources
Clinical operations and revenue cycle

CLEW ICU

CLEW describes CLEW ICU as an AI-driven clinical surveillance platform for high-acuity care with FDA-cleared class II predictive models; FDA records list K233216 for the CLEWICU System as a medium-term adjunctive predictive cardiovascular indicator with a January 13, 2024 substantial-equivalence decision.

Best for
Hospitals evaluating predictive surveillance for high-acuity units where ICU teams can govern alert routing, escalation, and local performance monitoring.
First check
FDA 510(k) K233216 intended use, adult critical-care setting, product code, decision date, and any predetermined change-control plan boundaries.
Sources
6 official sources

Official source trail for this workflow

Open these vendor, documentation, privacy, or regulatory sources before relying on product claims, especially for FDA status, PHI handling, deployment model, and intended use.

Compare clinical operations and revenue cycle products · Open the category shortlist · Review source policy

Related medical AI guides